Hologic has launched its molecular diagnostic system, Novodiag, for on-demand molecular testing in Europe.

The launch of the fully automated solution comes after the company’s acquisition of Finnish-French molecular diagnostic test developer Mobidiag in June.

The small, quiet and stackable platform is designed for the on-demand testing of infectious diseases and antimicrobial resistance.

It combines real-time polymerase chain reaction (PCR) with microarray capabilities to enable the identification of multiple pathogens in a single sample.

This provides a simple and quick way to identify patients who are at risk with targeted, multiplex and syndromic on-demand testing.

The new solution is precision engineered for affordability, simplicity and accuracy across a broad menu of high and low plex tests.

Novodiag’s CE-IVD test menu includes on-demand assays screening antibiotic resistance and gastrointestinal infections along with a targeted assay to detect SARS-CoV-2, the virus which causes Covid-19.

The company stated that the new molecular diagnostic solution launch brings benefits to a broad range of European customers and expands its molecular scalable solutions offering.

Hologic International group president Jan Verstreken said: “Our acquisition of Mobidiag was aimed at strengthening our international diagnostics business. With the Hologic launch of the Novodiag system, we are delivering against this goal.

“The addition of the Novodiag system to our diagnostic molecular scalable solutions portfolio will offer more customers in Europe a wider choice of solutions that meet their needs, from single patient rapid testing to population-level screening.”

The new solution complements the Hologic Panther system and Panther Scalable Solutions, allowing the growing diagnostic testing needs of customers to be met in both small and large laboratories.